Abbott Laboratories Corporation

Abbvie Inc.

Other

Medimmune Limited

Abbvie Deutschland Gmbh and Co Kg

Susan E Brophy

Bailin Tu

Joan D Tyner

David J Hawksworth

Robert N Ziemann

Bryan C Tieman

Larry G Birkenmeyer

Carol S Ramsay

Anthony Scott Muerhoff

Dinesh O Shah

Barry Lee Dowell

Robert William Siegel

Mary S Pinkus

Dagang Huang

Cheng Zhao

Lowell J Tyner, Legal Representative

Carolyn J Strobel

Sharmila Manoj

Philip M Hemken

Saul A Datwyler

Jessie W Shih

Dominick L Pucci

Zhiguang Yu

Tariq Ghayur

Partha S Chowdhury

Meina Liang

Bernhard K Mueller

Frank C Grenier

Reena Varkey

Jonathan P Belk

Jonathan Grote

Andreas Popp

Koustubh Ranade

Yen-Wah Lee

Elaine Marie Brate

Junjian Liu

Gangamani S Beligere

Bruce J Dille

Yihong Yao

Katie Streicher

David J Daghfal

Ethan Grant

Matthew S Matias

Lydia Greenlees

Melissa Parker

Gerard Davis

Don C Laird

David C Sogin

David J Dagfal

Don M Laird

Lianli Chi

Jan Schultess

Christian Beckert

Shamila Manoj

Nicolette Jeanblanc

Bryan Tieman

Joan D(deceased) Tyner

Barry L Dowell

James Scheffel

Joan D (Deceased) Tyner

Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.

Anti-GP73 monoclonal antibodies and methods of obtaining the same

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of using antibodies to determine periostin levels in a sample

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of

[object Object]

Provided herein are antibodies and methods of using the antibodies to treat, prevent, modulate, attenuate and diagnose iron-related disorders.

Composition and method for the diagnosis and treatment of iron-related disorders

The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.

Antibodies to troponin I and methods of use thereof

Vitamin D binding proteins (DBP), in particular truncated DBP and mutated, truncated DBP, as well as fusion proteins thereof, nucleic acid molecules encoding same, vectors, host cells, and methods, kits and solid supports for determining the total amount of 25-hydroxy vitamin Dand 25-hydroxy vitamin Din a test sample.

Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use

The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

PlGF-1 assay and kits and components thereof

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.

Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making

The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.

Human BNP immunospecific antibodies

Growing community of inventors

Lindenhurst, IL, United States of America

Susan E Brophy